SB 525334

• Description :

  SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H315, H319, H335, H413

• Target :

  TGF-β Receptor

• Type :

  Reference compound

• Related Pathways :

  TGF-beta/Smad

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/SB-525334.html

• Purity :

  99.97

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  CC(C)(C1=NC(C2=CC=CC(C)=N2)=C(C3=CC=C4N=CC=NC4=C3)N1)C

• Molecular Formula :

  C21H21N5

• Molecular Weight :

  343.42

• Precautions :

  H301, H315, H319, H335, H413

• References & Citations :

  [1]Grygielko ET, et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther, 2005, 313 (3), 943-951.|[2]Thomas M, et al. ALK5 mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am J Pathol, 2009, 174 (2), 380-389.|[3]Laping NJ, et al. Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. Clin Cancer Res, 2007, 13 (10), 3087-3899.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [356559-20-1]